Resources for
healthcare professionals


Shuford S, Wilhelm C, Rayner M, et al. Prospective validation of an ex vivo, patient-derived spheroid model for response predictions in newly diagnosed ovarian cancer. Sci Rep. 2019;9(1):11153.
Shuford S, Lipinski L, Abad A, et al. Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021;3(1).
Reed MR, Lyle AG, De Loose A, et al. A functional precision medicine pipeline combines comparative transcriptomics and tumor organoid modeling to identify bespoke treatment strategies for glioblastoma. Cells. 2021;10(12):3400.
Appleton KM, Elrod AK, Lassahn KA, Shuford S, Holmes LM, DesRochers TM. PD-1/PDL1 checkpoint inhibitors in combination with olarparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures. Cancer Immunol Immunother. 2021;70(3):843-856.


American Association for Cancer Research (AACR)
April 17, 2023

Preclinical testing of therapeutic biologics using patient-derived 3D spheroids.

April 16, 2023
Perfused patient-derived tumor organoid models with autologous immune cells for preclinical drug development.
June 5, 2022

Abstract ID 2031: Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.

April 13, 2022

Dissecting personalized PD-1 inhibitor efficacy using patient-derived 3D spheroids.

April 12, 2022

3D Predict™, an analytically and clinically validated platform for evidence-based functional precision medicine.


Organoids standardized to a clinically validated drugs response assay for truly predictive in vitro drug response profiling.

April 10, 2022

Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development.


Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response.


Engineered 3D tissues facilitate preclinical immunotherapy studies in fully human platforms.

Society for Neuro-Oncology (SNO)
November 18, 2022

Functional ex vivo testing prospectively identifies newly diagnosed glioblastoma patients sensitive to temozolomide treatment irrespective of MGMT methylation status.

Society for Immunotherapy of Cancer (SITC)
November 11, 2022

Abstract #162: Detecting T-cell reinvigoration and persistence using patient-derived ex vivo three-dimensional spheroid models.



Analyzing the modeling of T-cell specific immunotherapies

Kiyatec’s innovative ex vivo human tumor models, featuring a combination of tumor cells, stromal cells, and autologous immune cells, serve as a crucial tool in mitigating risks in preclinical immunotherapy development. These models enable the study of T-cell persistence and activity within ex vivo cultures, showcasing their potential utility in assessing T-cell specific therapies, including checkpoint inhibitors, bispecifics, and cellular therapies.

Presented by Tessa DesRochers, PhD
7th Tumor Models for Immuno-Oncology Summit
January 25, 2023
San Francisco



Ex vivo 3D cell culture technology for predicting individualized therapeutic response.

watch video

Microtumor technology for investigating long-term drug response.

watch video

Case studies

Session 1 presented April 25, 2023, powered by OncoLens


Dr. Kester A. Phillips
Medical Director, Neuro-Oncology
Swedish Neuroscience Institute

Dr. Zachary Litvack
Co-Director, Neurosurgery
Swedish Neuroscience Institute

Case 1: 65-year-old male presenting with seizures

Diagnosis: GBM, WHO grade IV
Location: Right temporal occipital region
Molecular markers: MGMT unmethylated, IDH & ATRX wildtype, EGFR amplified
Recurrence at 1 year

watch video
Case 2: 23-year-old male

Diagnosis: Epithelioid GBM, WHO Grade IV
Location: Right parietal region
Molecular markers: MGMT unmethylated, IDH WT, H3 WT, BRAF V600E mutant, CDK2NA Homozygous Loss
Recurrence at 15 months

watch video

Session 2 presented June 9, 2023, powered by OncoLens


Dr. Maciej M. Mrugala, MD, PhD, MPH
Professor of Medicine and Neurology
Comprehensive Neuro-Oncology Program
Mayo Clinic
Phoenix, Arizona

Case 1: 37-year-old female

Original diagnosis (2008): Oligoastrocytoma, WHO grade II
Location: Right frontal region
5 Recurrences
Pathology (2023): High-grade astrocytoma
Molecular markers: IDH mutant, high TMB & MSI

watch video
Case 2: 33-year-old female

Diagnosis (2019): HGG, WHO Grade IV
Location: Right parietal region
Recurrence at 2 years
Molecular markers: BCOR alteration, MSI

watch video

Session 3 presented August 15, 2023, powered by OncoLens


Analiz Rodriguez, MD, PhD, MBA, FAANS
Director of Neurosurgical Oncology
Associate Professor and Vice Chair of Research
Department of Neurosurgery
University of Arkansas for Medical Sciences

Case 1: 25-year-old male

Original diagnosis (2019): Li Fraumeni
Location: Left temporal region
Pathology: GBM
Progressions: 5 surgeries for recurrent disease, Ommaya for intrathecal therapy

watch video
Case 2: 5-year-old male with Grade 4 IDHm astrocytoma in 2020

Original diagnosis (2013): WHO grade 2 astrocytoma
3rd craniotomy in 2019: WHO grade 3 astrocytoma
4th craniotomy in 2020: WHO grade 4 astrocytoma

watch video
Case 3: 59-year-old male with new onset seizures

Original diagnosis (2022): Presumed HSV Encephalitis
Location: Left temporal region
Central necrosis heterogeneous enhancement edema at 1 month

watch video

Session 4 presented February 22, 2023, powered by OncoLens


Yazmin Odia, MD, MS, FAAN
Chief of Neurology Oncology
Baptist Health Miami Cancer Institute

Case 1: 69-year-old female presented with balance issues, left facial droop, and left leg weakness

Pathology: WHO grade 4 glioblastoma, IDH-wildtype, MGMT unmethylated
Location: Right temporal lobe
Progression at 1 year

watch video
Case 2: 42-year-old female presented with headache, generalized tingling, and facial numbness

Pathology: WHO grade 4 glioblastoma, IDH-wildtype, MGMT unmethylated
Location: Lateral right frontal
Progression at 6 months

watch video
Case 3: 67-year-old female with seizures

Pathology: WHO grade 4 glioblastoma BRAF-V600E mutation
Location: Right temporoparietal
Progression at 7 years after treatment holiday

watch video
Case 4: 62-year-old male presented with expressive aphasia

Pathology: c/w glioblastoma, IDH-wildtype, MGMT methylated
Location: Left inferior temporal gyrus

watch video

Subscribe for news and updates.